JPWO2022078352A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022078352A5 JPWO2022078352A5 JP2023523059A JP2023523059A JPWO2022078352A5 JP WO2022078352 A5 JPWO2022078352 A5 JP WO2022078352A5 JP 2023523059 A JP2023523059 A JP 2023523059A JP 2023523059 A JP2023523059 A JP 2023523059A JP WO2022078352 A5 JPWO2022078352 A5 JP WO2022078352A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- disease
- ray powder
- powder diffraction
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/120814 | 2020-10-14 | ||
| CN2020120814 | 2020-10-14 | ||
| PCT/CN2021/123387 WO2022078352A1 (en) | 2020-10-14 | 2021-10-13 | Crystal forms of glp-1r agonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546125A JP2023546125A (ja) | 2023-11-01 |
| JPWO2022078352A5 true JPWO2022078352A5 (enExample) | 2024-10-21 |
| JP7769695B2 JP7769695B2 (ja) | 2025-11-13 |
Family
ID=78401981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523059A Active JP7769695B2 (ja) | 2020-10-14 | 2021-10-13 | Ｇｌｐ－１ｒアゴニストの結晶形態およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230382899A1 (enExample) |
| EP (1) | EP4228753B1 (enExample) |
| JP (1) | JP7769695B2 (enExample) |
| CN (1) | CN116710446B (enExample) |
| AU (1) | AU2021359493A1 (enExample) |
| CA (1) | CA3195264A1 (enExample) |
| ES (1) | ES3041328T3 (enExample) |
| TW (1) | TW202227421A (enExample) |
| WO (1) | WO2022078352A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3010351T3 (en) * | 2019-12-02 | 2025-04-02 | Hyundai Pharm Co Ltd | Glp-1 receptor agonist |
| AU2022349020A1 (en) | 2021-09-27 | 2024-05-09 | Terns Pharmaceuticals, Inc. | Benzimidazole carboxylic acids as glp-1r agonists |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JP2025508812A (ja) | 2022-02-23 | 2025-04-10 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒアゴニストとしての化合物 |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| JP2025523988A (ja) * | 2022-07-18 | 2025-07-25 | 徳睿智薬（蘇州）新薬研発有限公司 | Ｇｌｐ－１ｒアゴニストの結晶多形物並びにその製造方法及び使用 |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP5382952B2 (ja) | 2008-03-07 | 2014-01-08 | トランス テック ファーマ，インコーポレイテッド | 糖尿病の治療のためのオキサジアゾアントラセン化合物 |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CN110325530B (zh) | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| PL3806855T3 (pl) | 2018-06-15 | 2023-07-24 | Pfizer Inc. | Agoniści receptora GLP-1 oraz ich zastosowania |
| EP3883928A4 (en) * | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| PH12021552557A1 (en) | 2019-04-12 | 2022-07-04 | Qilu Regor Therapeutics Inc | Glp-1r agonists and uses thereof |
| US10954221B2 (en) * | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
-
2021
- 2021-10-13 JP JP2023523059A patent/JP7769695B2/ja active Active
- 2021-10-13 ES ES21798552T patent/ES3041328T3/es active Active
- 2021-10-13 AU AU2021359493A patent/AU2021359493A1/en active Pending
- 2021-10-13 EP EP21798552.2A patent/EP4228753B1/en active Active
- 2021-10-13 CN CN202180082321.9A patent/CN116710446B/zh active Active
- 2021-10-13 TW TW110138006A patent/TW202227421A/zh unknown
- 2021-10-13 CA CA3195264A patent/CA3195264A1/en active Pending
- 2021-10-13 US US18/031,380 patent/US20230382899A1/en active Pending
- 2021-10-13 WO PCT/CN2021/123387 patent/WO2022078352A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4157832T3 (fi) | Glp-1r-agonistien suola- ja kidemuotoja ja niiden käyttötarkoituksia | |
| JP2021091683A5 (enExample) | ||
| JPWO2020103815A5 (enExample) | ||
| TWI864650B (zh) | Glp-1受體激動劑化合物之新穎鹽類、其製備方法以及包含其之醫藥組合物 | |
| DK2114934T3 (en) | COMPOSITION AND METHODS FOR MODULATING A kinase cascade | |
| JP2023502619A (ja) | Ｇｌｐ－１受容体アゴニストおよびその使用 | |
| JPWO2022078352A5 (enExample) | ||
| TWI720803B (zh) | 製備ｐｄｅ４抑制劑之方法 | |
| CN119487023A (zh) | Glp-1r激动剂的盐及其制备方法和应用 | |
| JP2021073256A5 (enExample) | ||
| EP4585593A1 (en) | Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof | |
| CN117417330A (zh) | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 | |
| CN117417329A (zh) | 一种glp-1r激动剂的多晶型物及其制备方法与用途 | |
| JP2021073259A5 (enExample) | ||
| RU2023112071A (ru) | ТВЕРДЫЕ ФОРМЫ СОЛИ 2-((4-((S)-2-(5-ХЛОРПИРИДИН-2-ил)-2-МЕТИЛБЕНЗО[d][1,3]ДИОКСОЛ-4-ИЛ)ПИПЕРЕДИН-1-ИЛ)МЕТИЛ)-1-(((S)-ОКСЕТАН-2-ИЛ)МЕТИЛ)-1H-БЕНЗО[d]ИМИДАЗОЛ-6-КАРБОНОВОЙ КИСЛОТЫ С 1,3-ДИГИДРОКСИ-2-(ГИДРОКСИМЕТИЛ)ПРОПАН-2-АМИНОМ | |
| JP4740875B2 (ja) | アムロジピンのゲンチシン酸塩及びその製造方法 | |
| CN106458904A (zh) | N‑取代磺酰胺化合物及其制造方法 | |
| RU2024105013A (ru) | Твердые формы 2-[(4-{ 6-[(4-циано-2-фторбензил)окси]пиридин-2-ил} пиперидин-1-ил)метил]-1- [(2s)-оксетан-2-илметил]-1hбензимидазол-6-карбоновой кислоты, 1,3-дигидрокси-2- (гидроксиметил)пропан-2-аминной соли | |
| EP4559910A1 (en) | Polymorphic form of glp-1r agonist, preparation method therefor and use thereof | |
| RU2025104879A (ru) | Полиморф соединения-агониста glp-1r, способ его получения и его применение | |
| RU2025102482A (ru) | Соль агониста glp-1r, способ ее получения и ее применение | |
| CN119816494B (zh) | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 | |
| RU2021131781A (ru) | Агонисты glp-1r и их применения | |
| TH2101006375A (th) | อะโกนิสต์ glp-1r และการใช้สิ่งนั้น | |
| TW202515865A (zh) | 製備取代的稠合咪唑衍生物的方法 |